<DOC>
	<DOCNO>NCT00294658</DOCNO>
	<brief_summary>The purpose trial determine thymectomy combine prednisone therapy beneficial treat non-thymomatous myasthenia gravis prednisone therapy alone .</brief_summary>
	<brief_title>Thymectomy Trial Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy</brief_title>
	<detailed_description>Myasthenia gravis ( MG ) autoimmune disease involve thymus 85 percent patient antibody muscle acetylcholine receptor ( AchR-Ab ) interfere neuromuscular transmission . MG frequently cause severe disability life-threatening . Thymectomy—a surgical procedure remove thymus gland tissue chest cavity—has establish therapy non-thymomatous MG , MG without thymoma , 60 year ( base retrospective , non-randomized study ) . Corticosteroids use increasingly either sole treatment combination thymectomy . Both therapy associate adverse effect indication use base randomized trial data lacking . The purpose 5-year trial determine surgical procedure , extend transsternal thymectomy ( ETTX ) , combine prednisone therapy beneficial treating individual non-thymomatous MG prednisone therapy alone . More specifically , study determine 1 ) ETTX combine prednisone result great improvement myasthenic weakness , compare prednisone alone ; 2 ) ETTX combine prednisone result low total dose prednisone , thus decrease likelihood concurrent long-term toxic effect , compare prednisone alone ; 3 ) ETTX combine prednisone enhances quality life reduce adverse event symptom associated therapy , compare prednisone alone . Learning thymectomy result meaningful reduction prednisone dosage even full withdrawal reduces side effect relate prednisone would support use two treatments—thymectomy prednisone—together . However , meaningful reduction prednisone dosage side effect show , result would mean use two treatment together offer advantage prednisone treatment alone . After initial screening , study participant randomize either undergo surgical procedure ETTX receive prednisone treatment , receive prednisone treatment alone without surgery . Participants follow least 3 year .</detailed_description>
	<mesh_term>Muscle Weakness</mesh_term>
	<mesh_term>Myasthenia Gravis</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Male female MG patient age great 18 less 65 year Onset generalize MG within last 5 year Positive serum antiacetylcholine receptor bind antibody ( muscle acetylcholine receptor , AchRAb =/ &gt; 1.00 nmol/L . AchRAb level 0.500.99 nmol/L acceptable another confirmatory test MG , include singlefiber electromyography ( EMG ) , repetitive nerve stimulation , unequivocal edrophonium test . ) MGFA class IIIV entry , use MG Foundation America ( MGFA ) classification , receive optimal anticholinesterase treatment without oral prednisone Ocular MG without generalize weakness ( MGFA Class I ) minimal weakness would require use corticosteroid Myasthenic weakness require intubation ( MGFA Class IV ) prior month Immunosuppressive therapy corticosteroid precede year Medically unfit thymectomy Chest CT evidence thymoma . Pregnancy lactation ; contraindication use corticosteroid , unless postmenopausal surgically sterile . Women consider become pregnant period study exclude . A serious concurrent medical , neurological psychiatric condition would interfere thymectomy subsequent clinical assessment Current alternate day dose prednisone &gt; 1.5 mg/kg 100 mg equivalent daily dos ( &gt; 0.75 mg/kg 50 mg ) . Participation another experimental clinical trial History alcohol drug abuse within 2 year prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>myasthenia gravis</keyword>
	<keyword>thymectomy</keyword>
	<keyword>prednisone</keyword>
	<keyword>corticosteroid</keyword>
	<keyword>extend transsternal thymectomy</keyword>
	<keyword>ETTX</keyword>
	<keyword>MG</keyword>
	<keyword>thymus</keyword>
	<keyword>thymoma</keyword>
</DOC>